The Rhesus Factor D, or Rh Factor, is a protein found on the surface of red blood cells. If your red blood cells have this protein, you are considered RhD positive; if not, you are RhD negative.
Fetal RhD screening helps determine the baby’s RhD status, which is crucial for managing pregnancy in RhD negative women and preventing complications for both the mother and the child.
Rhesus D Track
What is Non-Invasive RhD Testing?
Non-invasive RhD testing is a prenatal screening method designed to detect the Rhesus D (RhD) status of a fetus using the mother’s blood. The fetal RhD screening test employs real-time quantitative polymerase chain reaction (PCR) technology to analyse cell-free fetal DNA from RhD-negative pregnant women. This fetal RhD screening helps healthcare providers identify whether the fetus is RhD-positive or RhD-negative, enabling targeted administration of anti-RhD immunoglobulin when necessary. MedGenome offers the non-invasive RhD test for tailoring management based on results.
Benefits of Early RhD Detection
| Parameter | Details | |
|---|---|---|
| Invasive Procedures | Women undergoing amniocentesis or chorionic villus sampling (CVS). | |
| Medical Termination of Pregnancy | Ensures informed care if undergoing MTP or abortion. | |
| Sensitising Events | Helps manage cases with potential sensitising events during pregnancy. | |
| Ectopic Pregnancy | Can be valuable for ectopic pregnancy management. |
Clinical Indications of Non-Invasive RhD Testing
- Pregnant women who are RhD-negative.
- Pregnancies from 11 weeks of gestation onward.
- Best suited for singleton pregnancies
Specifications
- Sample Type: Maternal peripheral blood
- Sample Requirement: 10 ml
- Collection Tube: Collected in a Streck™ tube to stabilise fetal DNA
- Methodology: Quantitative real time PCR
Non-Invasive RhD Test Offered by MedGenome
Non-Invasive Fetal Rhesus (RhD) Genotyping
-
Detect: Fetal RhD status using cell-free fetal DNA in RhD negative women.
-
TAT: 14 working days
-
Test Code: MGM2556
Key Highlights of MedGenome's Non-Invasive RhD Test
Non-Invasive and Safe
The test requires only a maternal blood sample, making it safe for both the mother and fetus.
Early Detection
Fetal RhD status can be detected as early as 11 weeks, allowing clinicians to act promptly.
Highly Accurate Results
Using advanced real-time PCR technology, this test delivers reliable and precise results.
Get Genetic Counselling by Our Experts
Connect with Our Experts
MedGenome Patient Stories
MedGenome in the News
Please share your details to get
in touch with our experts.
